Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Johnson & Johnson Debuts Global Public Health Program

By Andy Szal | April 7, 2016

Johnson & Johnson this week unveiled a new global public health initiative stemming from a new facility in South Africa.

The New Jersey-based pharmaceutical and consumer products giant officially opened its Cape Town operations on Tuesday and detailed plans to help bolster health care across the continent and world.

J&J said that public health staff, as well as representatives from its various companies, will focus on end-to-end health needs including education and training, research and development and manufacturing and distribution.

Company teams will also help translate those efforts into programs that can be executed in communities with local health partners.

The initial phase will focus on HIV, tuberculosis and maternal, newborn and child health in South Africa.

“This is a model based on innovation, collaboration, and local empowerment that aims to address life threatening issues and deliver measurable results to improve outcomes for patients, families and communities, first across Africa, and more globally in the longer term,” J&J Pharmaceuticals Chief Scientific Officer Paul Stoffels said in a statement.

The announcement detailed several new and recent partnerships, including initiatives to prevent the spread of HIV among adolescent girls and to improve health care delivery in low-income areas. The latter effort will begin with 19 clinics before expanding to 50 throughout South Africa.

Johnson & Johnson teams will also work with academic centers and entrepreneurs to establish incubators for medical startups.

The company expects to establish satellite public health offices later this year in Kenya and Ghana and, eventually, expand both its geographic reach and its health targets.

“Ultimately, we’re aspiring to build a healthy world free of disease and our approach here is a potential blueprint for helping us and others succeed against that broader, global goal in the future,” said Chairman and CEO Alex Gorsky.

The program is also expected to increase investment in Johnson & Johnson’s current operations in Africa, which includes three manufacturing plants and more than 1,500 employees.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE